These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 10536125)

  • 1. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza.
    Hayden FG; Atmar RL; Schilling M; Johnson C; Poretz D; Paar D; Huson L; Ward P; Mills RG
    N Engl J Med; 1999 Oct; 341(18):1336-43. PubMed ID: 10536125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group.
    Hayden FG; Osterhaus AD; Treanor JJ; Fleming DM; Aoki FY; Nicholson KG; Bohnen AM; Hirst HM; Keene O; Wightman K
    N Engl J Med; 1997 Sep; 337(13):874-80. PubMed ID: 9302301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment.
    Hayden FG; Treanor JJ; Fritz RS; Lobo M; Betts RF; Miller M; Kinnersley N; Mills RG; Ward P; Straus SE
    JAMA; 1999 Oct; 282(13):1240-6. PubMed ID: 10517426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group.
    Hayden FG; Gubareva LV; Monto AS; Klein TC; Elliot MJ; Hammond JM; Sharp SJ; Ossi MJ;
    N Engl J Med; 2000 Nov; 343(18):1282-9. PubMed ID: 11058672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral oseltamivir in human experimental influenza B infection.
    Hayden FG; Jennings L; Robson R; Schiff G; Jackson H; Rana B; McClelland G; Ipe D; Roberts N; Ward P
    Antivir Ther; 2000 Sep; 5(3):205-13. PubMed ID: 11075941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial.
    LaForce C; Man CY; Henderson FW; McElhaney JE; Hampel FC; Bettis R; Kudule L; Harris J; Yates P; Tisdale M; Webster A
    Clin Ther; 2007 Aug; 29(8):1579-90; discussion 1577-8. PubMed ID: 17919541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy and safety of the selective oral neuraminidase inhibitor oseltamivir for prophylaxis against influenza--placebo-controlled double-blind multicenter phase III trial].
    Kashiwagi S; Kudoh S; Watanabe A; Yoshimura I
    Kansenshogaku Zasshi; 2000 Dec; 74(12):1062-76. PubMed ID: 11193558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oseltamivir: a review of its use in influenza.
    McClellan K; Perry CM
    Drugs; 2001; 61(2):263-83. PubMed ID: 11270942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group.
    Treanor JJ; Hayden FG; Vrooman PS; Barbarash R; Bettis R; Riff D; Singh S; Kinnersley N; Ward P; Mills RG
    JAMA; 2000 Feb; 283(8):1016-24. PubMed ID: 10697061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study.
    Mäkelä MJ; Pauksens K; Rostila T; Fleming DM; Man CY; Keene ON; Webster A
    J Infect; 2000 Jan; 40(1):42-8. PubMed ID: 10762110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuraminidase inhibitors: zanamivir and oseltamivir.
    McNicholl IR; McNicholl JJ
    Ann Pharmacother; 2001 Jan; 35(1):57-70. PubMed ID: 11197587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children.
    Belshe RB; Mendelman PM; Treanor J; King J; Gruber WC; Piedra P; Bernstein DI; Hayden FG; Kotloff K; Zangwill K; Iacuzio D; Wolff M
    N Engl J Med; 1998 May; 338(20):1405-12. PubMed ID: 9580647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor.
    Sidwell RW; Huffman JH; Barnard DL; Bailey KW; Wong MH; Morrison A; Syndergaard T; Kim CU
    Antiviral Res; 1998 Feb; 37(2):107-20. PubMed ID: 9588843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial.
    Fry AM; Goswami D; Nahar K; Sharmin AT; Rahman M; Gubareva L; Azim T; Bresee J; Luby SP; Brooks WA
    Lancet Infect Dis; 2014 Feb; 14(2):109-18. PubMed ID: 24268590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations.
    Kaiser L; Wat C; Mills T; Mahoney P; Ward P; Hayden F
    Arch Intern Med; 2003 Jul; 163(14):1667-72. PubMed ID: 12885681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households.
    Monto AS; Pichichero ME; Blanckenberg SJ; Ruuskanen O; Cooper C; Fleming DM; Kerr C
    J Infect Dis; 2002 Dec; 186(11):1582-8. PubMed ID: 12447733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral drugs in influenza: an adjunct to vaccination in some situations.
    Prescrire Int; 2006 Feb; 15(81):21-30. PubMed ID: 16548114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment.
    Barroso L; Treanor J; Gubareva L; Hayden FG
    Antivir Ther; 2005; 10(8):901-10. PubMed ID: 16430195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of oral oseltamivir for influenza prophylaxis in transplant recipients.
    Ison MG; Szakaly P; Shapira MY; Kriván G; Nist A; Dutkowski R
    Antivir Ther; 2012; 17(6):955-64. PubMed ID: 22728756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of the neuraminidase inhibitor zanamivir in treating influenza virus infection in adults: results from Japan. GG167 Group.
    Matsumoto K; Ogawa N; Nerome K; Numazaki Y; Kawakami Y; Shirato K; Arakawa M; Kudoh S; Shimokata K; Nakajima S; Yamakido M; Kashiwagi S; Nagatake T
    Antivir Ther; 1999; 4(2):61-8. PubMed ID: 10682150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.